Protocol Ledger

NCT03505710 · Phase II · TERMINATED

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT03505710 sponsored by Daiichi Sankyo in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-21 Enrollment: 181 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03505710
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)181 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03505710
Protocol FieldVerified Registry Value
NCT IdentifierNCT03505710
Consolidated Lead SponsorDaiichi Sankyo
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment181 participants (ACTUAL)
Registered Start Date2018-05-21
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI